Global and China Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights, Forecast to 2026
Table of Contents1 Study Coverage
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Product Introduction
1.2 Market Segments
1.3 Key Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type
1.4.2 Semi-Synthetic Penicillin
1.4.3 Cephalosporin
1.4.4 Lactam Drugs
1.4.5 Others
1.5 Market by Application
1.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Estimates and Forecasts
2.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2015-2026
2.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2015-2026
2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Resistant Pseudomonas Aeruginosa Infections Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Region (2021-2026)
3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Competitor Landscape by Players
3.1 Global Top Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers
3.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers by Revenue
3.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2019
3.2.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturers
3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base Distribution, Product Types
3.4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Resistant Pseudomonas Aeruginosa Infections Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type (2015-2020)
4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020)
4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2015-2020)
4.1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application (2015-2020)
5.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020)
5.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2015-2020)
5.1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2015-2020)
5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price Forecast by Application (2021-2026)
6 China by Players, Type and Application
6.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
6.1.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales YoY Growth 2015-2026
6.1.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue YoY Growth 2015-2026
6.1.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Share in Global Market 2015-2026
6.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Resistant Pseudomonas Aeruginosa Infections Drugs Players by Sales (2015-2020)
6.2.2 China Top Resistant Pseudomonas Aeruginosa Infections Drugs Players by Revenue (2015-2020)
6.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2015-2020)
6.4 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price Forecast by Type (2021-2026)
6.5 China Resistant Pseudomonas Aeruginosa Infections Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2015-2020)
6.6 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Price Forecast by Application (2021-2026)
7 North America
7.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
7.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
7.2.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020)
7.2.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
8.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
8.2.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
8.2.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
10.2.1 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
10.2.2 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
11.2.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 ContraFect Corp
12.1.1 ContraFect Corp Corporation Information
12.1.2 ContraFect Corp Description and Business Overview
12.1.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
12.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.1.5 ContraFect Corp Recent Development
12.2 Inhibrx LP
12.2.1 Inhibrx LP Corporation Information
12.2.2 Inhibrx LP Description and Business Overview
12.2.3 Inhibrx LP Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.2.5 Inhibrx LP Recent Development
12.3 Achaogen Inc
12.3.1 Achaogen Inc Corporation Information
12.3.2 Achaogen Inc Description and Business Overview
12.3.3 Achaogen Inc Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.3.5 Achaogen Inc Recent Development
12.4 LegoChem Biosciences Inc
12.4.1 LegoChem Biosciences Inc Corporation Information
12.4.2 LegoChem Biosciences Inc Description and Business Overview
12.4.3 LegoChem Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
12.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.4.5 LegoChem Biosciences Inc Recent Development
12.5 Melinta Therapeutics Inc
12.5.1 Melinta Therapeutics Inc Corporation Information
12.5.2 Melinta Therapeutics Inc Description and Business Overview
12.5.3 Melinta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.5.5 Melinta Therapeutics Inc Recent Development
12.6 Novartis AG
12.6.1 Novartis AG Corporation Information
12.6.2 Novartis AG Description and Business Overview
12.6.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.6.5 Novartis AG Recent Development
12.7 AmpliPhi Biosciences Corp
12.7.1 AmpliPhi Biosciences Corp Corporation Information
12.7.2 AmpliPhi Biosciences Corp Description and Business Overview
12.7.3 AmpliPhi Biosciences Corp Sales, Revenue and Gross Margin (2015-2020)
12.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.7.5 AmpliPhi Biosciences Corp Recent Development
12.8 Biolytics Pharma
12.8.1 Biolytics Pharma Corporation Information
12.8.2 Biolytics Pharma Description and Business Overview
12.8.3 Biolytics Pharma Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.8.5 Biolytics Pharma Recent Development
12.9 Shionogi & Co Ltd
12.9.1 Shionogi & Co Ltd Corporation Information
12.9.2 Shionogi & Co Ltd Description and Business Overview
12.9.3 Shionogi & Co Ltd Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.9.5 Shionogi & Co Ltd Recent Development
12.11 ContraFect Corp
12.11.1 ContraFect Corp Corporation Information
12.11.2 ContraFect Corp Description and Business Overview
12.11.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
12.11.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
12.11.5 ContraFect Corp Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Resistant Pseudomonas Aeruginosa Infections Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of TablesTable 1. Resistant Pseudomonas Aeruginosa Infections Drugs Market Segments
Table 2. Ranking of Global Top Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Semi-Synthetic Penicillin
Table 5. Major Manufacturers of Cephalosporin
Table 6. Major Manufacturers of Lactam Drugs
Table 7. Major Manufacturers of Others
Table 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Resistant Pseudomonas Aeruginosa Infections Drugs as of 2019)
Table 18. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Price (2015-2020) (USD/Pcs)
Table 21. Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
Table 23. Date of International Manufacturers Enter into Resistant Pseudomonas Aeruginosa Infections Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2015-2020)
Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2015-2020)
Table 29. Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2026)
Table 31. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2015-2020)
Table 33. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2026)
Table 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Application (2021-2026)
Table 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2015-2020) (US$ Million)
Table 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 37. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) of Key Companies (2015-2020)
Table 38. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Company (2015-2020)
Table 39. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Company (2015-2020)
Table 40. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2015-2020)
Table 41. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2015-2020)
Table 42. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 43. China Resistant Pseudomonas Aeruginosa Infections Drugs Price (K Pcs) by Type (2015-2020)
Table 44. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2021-2026)
Table 45. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2021-2026)
Table 46. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 47. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2021-2026)
Table 48. China Resistant Pseudomonas Aeruginosa Infections Drugs Price (K Pcs) by Type (2021-2026)
Table 49. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2015-2020)
Table 50. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2015-2020)
Table 51. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 52. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2021-2026)
Table 53. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2021-2026)
Table 54. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 55. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2021-2026)
Table 56. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 57. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 58. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 60. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 61. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 62. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 63. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 64. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2015-2020) (K Pcs)
Table 65. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2015-2020)
Table 66. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2015-2020) (US$ Million)
Table 67. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2015-2020)
Table 68. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 69. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 70. Latin Americaa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 71. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 73. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 74. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 75. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 76. ContraFect Corp Corporation Information
Table 77. ContraFect Corp Description and Business Overview
Table 78. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product
Table 80. ContraFect Corp Recent Development
Table 81. Inhibrx LP Corporation Information
Table 82. Inhibrx LP Description and Business Overview
Table 83. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Inhibrx LP Product
Table 85. Inhibrx LP Recent Development
Table 86. Achaogen Inc Corporation Information
Table 87. Achaogen Inc Description and Business Overview
Table 88. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Achaogen Inc Product
Table 90. Achaogen Inc Recent Development
Table 91. LegoChem Biosciences Inc Corporation Information
Table 92. LegoChem Biosciences Inc Description and Business Overview
Table 93. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. LegoChem Biosciences Inc Product
Table 95. LegoChem Biosciences Inc Recent Development
Table 96. Melinta Therapeutics Inc Corporation Information
Table 97. Melinta Therapeutics Inc Description and Business Overview
Table 98. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Melinta Therapeutics Inc Product
Table 100. Melinta Therapeutics Inc Recent Development
Table 101. Novartis AG Corporation Information
Table 102. Novartis AG Description and Business Overview
Table 103. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. Novartis AG Product
Table 105. Novartis AG Recent Development
Table 106. AmpliPhi Biosciences Corp Corporation Information
Table 107. AmpliPhi Biosciences Corp Description and Business Overview
Table 108. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. AmpliPhi Biosciences Corp Product
Table 110. AmpliPhi Biosciences Corp Recent Development
Table 111. Biolytics Pharma Corporation Information
Table 112. Biolytics Pharma Description and Business Overview
Table 113. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 114. Biolytics Pharma Product
Table 115. Biolytics Pharma Recent Development
Table 116. Shionogi & Co Ltd Corporation Information
Table 117. Shionogi & Co Ltd Description and Business Overview
Table 118. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 119. Shionogi & Co Ltd Product
Table 120. Shionogi & Co Ltd Recent Development
Table 121. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 122. Key Challenges
Table 123. Market Risks
Table 124. Main Points Interviewed from Key Resistant Pseudomonas Aeruginosa Infections Drugs Players
Table 125. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List
Table 126. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of FiguresFigure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Product Picture
Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Semi-Synthetic Penicillin Product Picture
Figure 4. Cephalosporin Product Picture
Figure 5. Lactam Drugs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Home Care
Figure 11. Resistant Pseudomonas Aeruginosa Infections Drugs Report Years Considered
Figure 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2015-2026 (K Pcs)
Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region in 2019
Figure 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region in 2019
Figure 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2019
Figure 21. Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2019
Figure 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type in 2019
Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2019
Figure 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application in 2019
Figure 31. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2026 (K Pcs)
Figure 32. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2026 (US$ Million)
Figure 33. China Resistant Pseudomonas Aeruginosa Infections Drugs Market Share in Global Market 2015-2026
Figure 34. China 5 and 10 Largest Resistant Pseudomonas Aeruginosa Infections Drugs Players Market Share by Revenue in Resistant Pseudomonas Aeruginosa Infections Drugs in 2019
Figure 35. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2015-2020)
Figure 36. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 37. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Application (2015-2020)
Figure 38. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 39. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 40. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 42. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 43. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 44. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 48. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 49. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 50. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 51. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (201